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ABSTRACT The solution structure and dynamics of the human coagulation factor X (FX) have been investigated to
understand the key structural elements in the zymogenic form that participates in the activation process. The model was
constructed based on the 2.3-Å-resolution x-ray crystallographic structure of active-site inhibited human FXa (PDB:1XKA).
The missing -carboxyglutamic acid (GLA) and part of epidermal growth factor 1 (EGF1) domains of the light chain were
modeled based on the template of GLA-EGF1 domains of the tissue factor (TF)-bound FVIIa structure (PDB:1DAN). The
activation peptide and other missing segments of FX were introduced using homology modeling. The full calcium-bound
model of FX was subjected to 6.2 ns of molecular dynamics simulation in aqueous medium using the AMBER6.0 package.
We observed significant reorientation of the serine-protease (SP) domain upon activation leading to a compact multi-domain
structure. The solution structure of zymogen appears to be in a well-extended conformation with the distance between the
calcium ions in the GLA domain and the catalytic residues estimated to be 95 Å in contrast to 83 Å in the activated form.
The latter is in close agreement with fluorescence studies on FXa. The S1-specificity residues near the catalytic triad show
significant differences between the zymogen and activated structures.
INTRODUCTION
Human coagulation factor X (FX), a vitamin K (VKD)-
dependent plasma zymogen, plays a central role in the blood
coagulation cascade (Davie et al., 1991). It is synthesized in
the liver as a single-chain precursor. In plasma, FX circu-
lates as a two-chain glycoprotein (59 KDa). The light
chain is cleaved from the heavy chain during or after secre-
tion into the circulation. FX is composed of a 306-residue
heavy chain that is covalently linked by a disulfide bond to
a 139-residue light chain (Di Scipio et al., 1977). The
sequence of human FX is highly homologous to other VKD
blood coagulation factors such as VII, IX, and protein C and
shares similar structure-function relationships with the same
family of enzymes (Greer, 1981; Furie et al., 1982). Upon
activation by either the tissue factor (TF)-VIIa complex
(extrinsic pathway) or by the IXa-VIIIa complex (intrinsic
pathway) in the presence of phospholipids and calcium ions,
activated FX (FXa) associates with FVa on a phospholipid
surface to form the prothrombinase complex. This complex
activates prothrombin to thrombin in the presence of cal-
cium ions (Mann et al., 1990). Mutational reduction in the
functional activity of FX leads to a rare autosomal recessive
bleeding disorder (a moderate to severe bleeding) known as
Stuart-Prower factor deficiency (Telfer et al., 1956; Hougie
et al., 1957).
The primary sequence of the FX in the zymogenic form
is shown in Fig. 1 (Leytus et al., 1986). The standard FX
amino acid sequence numbering is used throughout the
paper (Leytus et al., 1986), and where necessary the chy-
motrypsin numbering is given with a three-letter amino acid
code with residue number in superscript. The light chain of
zymogenic FX contains three characteristic structural do-
mains, each of which possesses distinct functional proper-
ties (Leytus et al., 1986; Padmanabhan et al., 1993). The
-carboxyglutamic acid (GLA)-rich domain contains 11
GLA residues (Ala1-Gla39 represents the GLA domain).
The GLA domain is followed by a short hydrophobic stack
(residues Phe40-Lys45) and two epidermal growth factor
(EGF)-like domains: EGF1 (Asp46-Phe84) and EGF2
(Thr85-Gly128).
The activation peptide (AP) consists of 52 residues
(Ser143-Arg194) in a 68-amino-acid external disulfide loop
between Cys132 and Cys302. In the circulating form of FX,
a set of cleavages has already removed residues Arg140-
Arg142. The heavy chain of FX contains the serine protease
(SP) domain of 254 amino acids (residues Ile195-Lys448),
which features the active-site catalytic triad of His236
(His57), Asp282 (Asp102), and Ser379 (Ser195). The proteo-
lytic activation of FX is accomplished by the cleavage of the
Arg194-Ile195 bond, which releases the AP. The activation
peptide of FX is glycosylated with carbohydrate chains
linked to Asn181, Asn191 (Jackson, 1984; Di Scipio et al.,
1977) and possibly Thr159 and Thr171 (Inoue and Morita,
1993; Nakagawa et al., 1995). Additional auto-proteolysis
of FXa at the Arg429-Gly430 peptide bond leads to the
removal of a small peptide from the carboxyl terminus of
the heavy chain that converts the -form of FXa to the
-form (Mertens and Bertina, 1980). However, no differ-
ence in function has yet been observed between the two
forms (Pryzdial and Kessler, 1996). Activation of FX by the
extrinsic Xase complex involves the factor VIIa/TF com-
plex, phospholipid, and calcium ions. Similarly, the intrinsic
Xase complex involves the FIXa/FVIIIa complex, phospho-
lipid, and calcium ions. Activation of FX by either of these
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complexes is selective and involves specific interactions
between the substrate (FX) and enzyme (TF/VIIa or VIIIa/
IXa). The structural details of such extended interactions
between the FX and enzyme complex are only beginning to
be understood. In addition, the existing x-ray structural
information about the FXa is incomplete. A complete solu-
tion structure of FX in both zymogenic and activated forms
is prerequisite to understand how the enzyme complex binds
to the substrate (FX) and initiates the activation process
through specific extended multi-site interactions that control
stereochemical accessibility of the scissile bond in FX (Fu-
jikawa et al., 1974; Nemerson, 1988; Ruf and Edgington,
1994; Stubbs and Bode, 1995; Betz and Krishnaswamy,
1998). Recent experimental studies identify the specific
residues in the extrinsic Xase complex, particularly in TF,
involved in the activation process (Dittmar et al., 1997; Ruf
et al., 1999). Similarly, specific residues in FX that may be
involved in the enzyme-substrate complex (Huang et al.,
1996) have also been identified. Given the available exper-
imental information about the contact residues, it may be
possible to construct the substrate-enzyme models once the
complete structure of zymogenic FX is available.
In the present work, we have constructed a full model of
solvent-equilibrated zymogenic FX based on the x-ray
structure of FXa using homology modeling and molecular
dynamics (MD) studies. The solvent-equilibrated simula-
tion structure of FX is compared with the x-ray crystal
structure of FXa as well as a solution structure of the FXa
determined in a parallel simulation to understand the mo-
lecular details of both structures, inter-domain arrangement,
and conformational changes that are triggered by activation.
Although the present work attempts to understand the subtle
structural differences between FX and FXa, the complete
calcium-bound solution structure of FX and FXa may also
be useful for constructing the macromolecular extrinsic
Xase and prothrombinase complexes, respectively.
FIGURE 1 Schematic representation of the primary
amino acid sequence of the two-chain human factor X.
The tripeptide of Arg140-Lys141-Arg142 that con-
nects the light chain to the activation peptide is not
shown because the form that lacks the tripeptide is
predominant in circulating blood plasma. Individual
domains are shown in boxes, functionally important
catalytic residues are circled, and  represents GLA
(-carboxyglutamic acid) residue.
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COMPUTATIONAL METHODS
Model building
The starting coordinates for the human FX and FXa were based on the
x-ray structure of the active-site-inhibited human FXa (Kamata et al.,
1998), solved at 2.3-Å resolution (Protein Data Bank (PDB) entry 1XKA).
Several x-ray crystal structures of FXa bound by several different inhibi-
tors have been solved (Padmanabhan, et al., 1993; Brandsetetter et al.,
1996; Kamata et al., 1998). These structures were solved invariably with
the GLA domain cleaved due to the experimental limitations in controlling
auto-proteolytic activity. From these, we chose 1XKA as a reasonable
starting structure to build the models of FX and FXa because it is the only
structure reported so far that contains most of the EGF2 and SP domains,
and also a larger part of EGF1 domain that is needed for proper modeling
of the GLA-EGF1 inter-domain orientation. The N-terminus of 1XKA
begins with residue GLN49. The calcium ion in the calcium-binding region
of the SP domain is present whereas the calcium ion that binds to the
GLA-EGF1 inter-domain is absent. Also, the residues Gly430-Lys448 in
the C-terminal end of the heavy chain are absent. The missing GLA domain
and part of EGF1 domains are constructed using the TF/VIIa x-ray crystal
structure (Banner et al., 1996). Recent MD studies suggested that the
isolated light chain of FVIIa is conformationally similar to TF-bound
FVIIa (Perera et al., 1999). The backbone of the FVIIa light chain thus
serves as a template for constructing the light-chain part of FX by com-
parative modeling. Initially, the Ala1-Ser60 fragment of FVIIa, together
with the bound calcium ions in the TF-FVIIa complex (1DAN), was used
to construct the GLA domain and missing EGF1 residues (Ala1-Asp48) of
FX. The residues of FVIIa were mutated to the corresponding residues in
the GLA domain of FX and energy minimized with the calcium ion
coordination to the GLA residues fixed. The residues Cys50-Cys55 in FX
were used to align with the corresponding residues in the FVIIa so as to
provide the appropriate orientation of the GLA-EGF1 domains. The miss-
ing calcium ion bound to the EGF1 domain was introduced by overlapping
the structurally conserved residues Asp46, Gly47, Gln49, -hydroxy as-
paratic acid (Bha63), and Gly64 with corresponding residues in FVIIa. The
coordinates of the seven calcium ions (bound to the GLA and GLA-EGF1
interface) from the superimposed FVIIa were transferred to the FX model.
FX also has additional GLA residues at positions 32 and 39, and two
calcium ions were introduced with a malonate coordination at these posi-
tions. The crystallographic water molecules in FXa (crystal) were retained
in the zymogen model to preserve the core water molecules involved in the
specific hydrogen bonding with the protein residues.
Human FX has a 55-residue activation peptide (AP) connecting
Arg139 at the C-terminal end of the light chain with the N-terminal
Ile195 of the heavy chain. Detailed analysis of the activated and
zymogenic SP structures (chymotrypsinogen, prethrombin, and propro-
teinase-E and their active forms) showed that significant reorientation
of the N-terminus of the heavy chain occurs upon activation of the
respective zymogens (Perera et al., 2000). In these activated SPs, the
N-terminal Ile16 is found to project into the core of the SP domain, near
the catalytic triad, and makes a salt bridge between the NH3 group of
Ile16 and the carboxylate of Asp194. To prepare the zymogenic form of
FX, we used the backbone of the SP domain in chymotrypsinogen (PDB
entry 2CGA) as the template to provide the appropriate orientation of
the N-terminus of heavy chain of the zymogen. When the active-site
residues His236 (His52), Asp282 (Asp102), and Ser379 (Ser195) of the
SP domain in the FXa structure are superimposed with corresponding
residues in chymotrypsinogen, distinct conformational differences be-
tween chymotrypsinogen and FXa were observed. The superimposed
structures of x-ray-derived activated factors Xa (1XKA), chymotrypsin
(4CHA), and the zymogenic structures of chymotrypsinogen (2CGA)
and prethrombin (1HAG) are shown in Fig. 2. The orientation of the
FIGURE 2 Conformational differences among the N-terminal end of the SP domain in the zymogen and the activated serine proteases. The illustration
is based on the backbone alignment (C) of the active site residues in the crystal structures of prethrombin, chymotrypsinogen, and their activated forms
(-thrombin and chymotrypsin). X-ray crystal structure of FXa is also shown in the figure. The labels in the figure correspond to chymotrypsin numbering.
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N-terminal end of activated factors is distinctly different from their
precursor zymogenic SP domains. Almost all of the SP domains of
activated VKD protein structures have similar orientation of the N-
terminus and ion-pair formation with Asp194. The chymotrypsinogen
residues Val9-Glu20 (corresponds to residues Asp189 to Glu200 in FX)
were used to extend the N-terminus of the heavy chain of FX. These
residues were changed to the corresponding residues of FX. Based on
the reconstructed N-terminus of the heavy chain, the missing 55-residue
AP was introduced using a loop search algorithm (SYBYL6.5 package,
Tripos Associates, St. Louis, MO). Within the conformational space
available between the C-terminal end of the light chain, Arg139, and the
N-terminal end of the heavy chain, Asp189, the loop search returned 25
loops, of which only 3 were found to be viable models within the
conformational space available for constructing the AP (with sequence
homology above 50%). Among the three loops, we chose the loop that
has the scissile bond Arg194-Ile195 well exposed for possible unhin-
dered interaction with incoming activation enzyme complexes. Also,
the chosen loop segment was spatially near the calcium-binding site in
the SP domain. FX is cleaved at Arg139 during or after secretion into
the blood plasma, and this process releases the tripeptide R140-K141-
R142. The light chain of the resulting two-chain FX is connected to the
heavy chain through a disulfide bond (Leytus et al., 1986). Because the
circulating blood plasma contains the zymogenic state of FX with
Arg140-Arg142 missing, these three residues connecting the light chain
with the AP were removed. Finally, the missing C-terminus residues
(Gly430-Lys448) of FX were introduced using homology modeling.
Although the AP in FX is glycosylated at four sites, the present model
does not contain the sugar residues. The human FXa crystal structure
reported by Padmanabhan et al., 1993) (PDB entry 1HCG) has the
C-terminus residues Gly430-Lys435 in the heavy chain that are missing
in 1XKA. After overlapping the backbone atoms of 1HCG with the
current model, the coordinates for Gly430-Lys435 were transferred
from 1HCG to the current model. The remaining missing C-terminal
residues from Ser436 to Lys448 were introduced using the loop-search
algorithm in SYBYL program.
In addition to the full model of zymogen of FX, we have also modeled
FXa. We used the final snapshot of the 6-ns trajectory from solvent-
equilibrated FX to model the light chain of FXa. Part of the light chain
comprising residues Ala1-Ser90, including the surrounding waters in the
solvation shell (a total of 5000 waters around residues Ala1-Thr85) found
within a 2-Å distance from any solute atom, of the simulation was used to
construct FXa. The EGF2 and SP domains of the x-ray crystal structure of
1XKA, including the water molecules found in the crystal structure, were
used in the model building. The backbone atoms of the residues Asn80-
Ser90 in the light-chain segment derived from the simulated FX and the
x-ray crystal structure were maximally aligned. The missing C-terminal
residues Gly430-Lys448 were introduced using part of the x-ray crystal
structure (1HCG) and loop-search methods of SYBYL in a manner similar
to zymogen modeling. The resulting initial structure of FXa was then
subjected to 3.2 ns of MD in aqueous solution.
Simulation setup
The molecular model of zymogenic FX together with the structural
waters derived from the x-ray crystal structure was subjected to mini-
mization. In the first step, the connecting region between the GLA and
EGF1 domains that binds a calcium ion was minimized while constrain-
ing the backbone. Similarly, the GLA domain and calcium ions coor-
dinated to the GLA residues were energy minimized while constraining
the backbone. Full minimization on the side chains of the entire protein
was performed while fixing the backbone to relieve bad contacts.
Minimization of the entire protein including the backbone was per-
formed for 1000 steps. The protein together with the crystal waters was
then placed in a box of water molecules with the box boundaries at least
12.0 Å from any given protein atom. Water molecules with oxygen
atoms closer than 2.0 Å to any protein atom were excluded. The
resulting periodic box comprised of 28,557 water molecules together
with 11 calcium ions bound. Because the system had a net negative
charge of 4, two uncoordinated calcium ions were added to maintain
electrical neutrality. The total number of solute and solvent atoms in the
periodic box was 92,513. The FXa model was subjected to a similar
simulation setup as described above. The net charge of the system was
a single positive charge; thus, a chloride counterion was added to
maintain the electrical neutrality. The system contained a total of
91,318 atoms.
The simulations in the present study were performed using the second
generation of the AMBER force-field (Cornell et al., 1995) and the
SANDER module of the AMBER6.0 package. Long-range interactions
were treated using the particle mesh Ewald (PME) method (Essman et al.,
1995). The PME charge grid spacing was 1.0 Å, and the charge grid was
interpolated using a cubic B-spline of order four, a direct sum tolerance of
0.00001, and a 9-Å direct space cutoff. Constant temperature and pressure
(300 K/L atm) were maintained throughout the simulations using the
Berendsen scaling algorithm with coupling constants of 0.2 ps (Berendsen
et al., 1984). All bonds involving hydrogen atoms were constrained using
the SHAKE algorithm. A time step of 2 fs was used to integrate the
equations of motion. Before beginning the production-run simulations, the
following equilibration protocol was followed. First, the water molecules
and counterions in the periodic box were energy minimized to a root mean
square (RMS) gradient of 0.1 kcal/mol/A2, followed by 10 ps of constant
pressure MD at 300 K. Second, the whole system, including solute (except
the backbone atoms, counterions, and water), was subjected to 1000 steps
of energy minimization to remove close contacts and to relax the system.
Finally, the whole system was subjected to energy minimization in 1000
conjugate gradient steps. The system was subjected to slow heat-up pro-
cedure to bring the system temperature to 300 K in six steps of 50°C/step
over 12 ps. The system was then energy minimized for 1000 steps and the
slow heat-up was repeated. After the system was brought up to 300 K, a
constant-volume/constant-temperature MD run was performed for 25 ps.
Finally, a constant-pressure/constant-temperature simulation was contin-
ued for 6.2 ns of MD with the coordinates written every 500 steps (1 ps).
The resulting trajectories were analyzed using the CARNAL module of
AMBER6.0. All simulations in the present work were carried out on a




The conformational changes that occur in the first 6.2 ns of
FX are presented. The simulated structure of FXa will be
used primarily for comparison with the predicted zymo-
genic structure. The equilibrated systems of FX and FXa
were found to be stable under constant (time and pressure)
conditions. The density of the system fluctuated near 0.99
g/cc during the post-equilibration period of the dynamics.
Fluctuations in the total energy of the system were relatively
low during the final 2 ns of the simulation. RMS fluctua-
tions during dynamics simulation can be used as a direct
measure of the stability of inter- and intra-domain move-
ments in the protein system. The atom-positional RMS
deviations (RMSDs) of the individual domains and the
whole protein are shown in Fig. 3, a–c. As shown in Fig. 3
a, the RMSDs of the protein backbone atoms for the system
(comparison with the initial structure, T  0 ps) stabilized
from 4 ns onwards (Fig. 3 a). The RMSD changes in the
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individual domains, GLA, EGF1, and EGF2, in the light
chain are also shown in Fig. 3 a. These individual domains
are remarkably stable over the simulation time. Similarly,
the SP and AP domains also maintain stable trajectories
during the simulation (Fig. 3 b). The inter-domain mo-
tions in the light chain, GLA-EGF1, EGF1-EGF2, and
the entire light chain are shown in the Fig. 3 c. Although
the individual domains of the light chain show small
RMS fluctuations (Fig. 3, a and b), the inter-domain
movement is clearly visible during the simulation. The
overall motion may be attributed to the inter-domain
motions between the GLA-EGF1 and EGF1-EGF2 do-
mains. In contrast to these inter-domain motions in the
light chain, the EGF2-SP and AP-SP interfaces maintain
stable inter-domain interactions (Fig. 3 b).
The atom-positional fluctuations in x-ray crystal struc-
tures are represented by atomic B-factors. Though it is
problematic to compare the crystallographic B-factors with
those derived from the aqueous-phase simulations due to
differences in the structural environment, time scales, and
techniques involved, the comparison of structural and sim-
ulation B-factors can be useful. The B-factors from the
x-ray crystal structure (FXa) for residues Gln49-Arg139 and
Ile195-Arg429 are compared with the B-factors calculated
(York et al., 1994) for corresponding C atoms in the
simulated FXa for light chain (Fig. 4, top) and heavy chain
(Fig. 4, bottom). The simulation values of the B-factors
were computed by two methods. In the first, the entire
protein was used in aligning the backbone atoms of the final
conformation of the trajectory (dotted line). In the second
method, each domain was individually aligned (solid line).
The B-factors of the x-ray crystal structure are also shown
in the figure (circles). The B-factors of the light chain are
significantly smaller when individual domains are aligned
as against the whole protein alignment. The inter-domain
flexibility in the light chain is likely responsible for such
large deviations when all residues are aligned. It is interest-
ing to note that the x-ray crystallographic B-factors are
somewhat comparable to the simulated FXa when the entire
protein is aligned. Although no experimental B-factors are
available for the GLA domain and part of the EGF1 do-
mains, the fluctuations in the computed B-factors are larger
in the GLA-EGF1 domains when the entire protein is
aligned. In contrast, the SP domain shows systematically
comparable values for the x-ray crystal and simulated FXa
B-factors. The flexible movement of the C-terminal end of
the SP domain is mirrored by corresponding larger B-
factors (Fig. 4, bottom). In general, the residues that have
larger B-factors in both x-ray crystal and simulated struc-
tures are invariably present in external loop regions (for
example, loop regions containing the residues Glu216,
Glu256, Glu277, Arg332, and Leu352). The core residues in
the SP domain, however, show rather smaller positional
fluctuations, indicating a stable tertiary structure of the core
residues.
Light chain
The light chain of FX consists of the GLA, EGF1, and
EGF2 domains. The calcium-rich GLA domain is respon-
FIGURE 3 The RMSDs of the back-
bone of various inter- and intra-domains
of FX when compared with the starting
conformation at T  0 ps. (a) All do-
mains aligned (——); separate align-
ments: Gla domain (E), EGF1 domain
(), and EGF2 domain (‚); (b) SP (E),
EGF2-SP (), AP (‚), and AP-SP (ƒ)
domains; (c) Inter-domain fluctuations:
Gla-EGF1-EGF2 (‚), EGF1-EGF2 (),
Gla-EGF1 (E).
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sible for binding to membranes, an essential step in the
coagulation process. The GLA domain and a portion of the
EGF1 domain that connects the GLA domain are necessar-
ily modeled in the present study. The initial structure of the
GLA domain and the relative orientation of GLA-EGF1
domains are based on the TF-bound FVIIa structure; the
6.2-ns simulation leaves the GLA-EGF1 orientation of FX
similar to the initial structure. The inter-domain movements
in the GLA-EGF1 domain of FX are significant as is evident
from the RMSDs shown in the Fig. 3 c. The backbone
superimposed structures of the GLA-EGF1 domains of
FVIIa (x-ray, PDB entry 1DAN), and FX (snapshot from
6.2 ns) with the positional alignment of the GLA-EGF1
domains (1–82 residues) are shown in Fig. 5. The RMSD
between the two structures (with backbone alignment of
residues 1–82 of GLA-EGF1 domains) is 2.2 Å, and the
corresponding RMSD between FVIIa and FXa (snapshot
from 3.2-ns trajectory) is 1.52 Å (not shown). This suggests
that FVIIa and FX/FXa share considerable conformational
similarity in the GLA-EGF1 domains.
The calcium (Ca2) binding to human FXa, particularly
the GLA-EGF1 segment, has been studied extensively by
several experimental methods. NMR studies on the GLA-
EGF1 fragment of FXa suggest that calcium binding in the
GLA domain plays a key role in reversible membrane
binding (Persson et al., 1991; Sunnerhagen et al., 1995). In
the calcium-bound form, the Gla residues ligate with Ca2
ions in the core of the GLA domain, forcing the side chains
of hydrophobic residues Phe4, Leu5, and Val8 into solvent.
In the calcium-free GLA domain, Gla residues are exposed
to solvent and Phe4, Leu5, and Val8 residues form a hy-
drophobic cluster in the interior of the protein (Sunnerha-
gen, et al., 1992, 1995). Likewise, a calcium ion binds at the
GLA-EGF1 hinge in several of the VKD proteins that
contain EGF domains. The relative orientation of GLA and
EGF1 domains is suggested to be more ordered in the
presence of calcium ion at the GLA-EGF1 inter-domain
region (Sunnerhagen et al., 1996). Recent time-resolved
fluorescence studies on the calcium-bound GLA-EGF1 do-
mains of FXa also suggest a change in the relative orienta-
FIGURE 4 The atomic B-factors evaluated us-
ing the last 200 ps of MD trajectory for backbone
C atoms for the zymogen with all residue align-
ment (  ) and individual domain alignment
(——) are shown for light chain (top) and heavy
chain (bottom). The x-ray crystallographic B-fac-
tors are also shown (E). B-factors are estimated
for the average structure of the last 200 ps of MD
trajectory against the snapshot of the MD trajec-
tory at 6100 ps. The individual domains of the
light chain are marked in vertical lines.
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tion of the GLA and EGF1 domains when the calcium ion
is bound to the GLA-EGF1 interface (Hafner et al., 2000).
In the absence of calcium ions, the GLA domain of FXa
does not bind to phospholipid surfaces (Stenflo and Suttie,
1977).
In the present model, we have added two calcium ions
to the carboxylate side chains of Gla residues at position
32 and 39 in addition to the seven calcium ions derived
from the GLA and EGF1 domains of the x-ray crystal
structure of TF-bound FVIIa. The GLA domain of FX is
homologous to the other VKD proteins (FII, FVII, FIX,
PC, PS, and PZ) and characterized by 11 GLA residues
with three conserved pairs present at positions 6:7, 19:20,
and 25:26 in all VKD proteins. In contrast to other VKD
factors, only FX and FIX have a GLA residue at position
39. The GLA domain maintains a stable trajectory during
the entire simulation time period as shown in Fig. 3 a.
The stability stems from the well coordinated GLA-
calcium network and the Ala1-Gla H-bonding network.
The calcium-bound GLA domain is shown in Fig. 6
together with the EGF1 domain (snapshot from 6.2-ns
trajectory). The unique H-bonding network at Ala1 in the
interior of the GLA domain with the four residues Gla16,
Gla20, Thr21, and Gla26 is well maintained in the current
simulations as for other VKD proteins (Perera et al.,
1999, 2000, 2001). Also, the -loop, formed by residues
Ala1-Gly11 and believed to be responsible for the bind-
ing of GLA domain to membrane surfaces (Welsch and
Nelsestuen, 1988), is stable during the simulation period.
The NH3
 of Ala1 is maintained in a stable H-bonding
network with atom O of Gla16 (3.56 Å), OE4 of GLA20
(2.88 Å), atom O of Thr21 (2.93 Å), and an ion-pair with
GLA26. Three hydrophobic residues (Phe4, Leu5, and
Met8) protrude outwards from the -loop throughout the
simulation period. The backbone atoms of the three res-
idues are H-bonded to each other and confer stability to
the -loop. These three residues have been implicated
for interactions with membrane (Zhang and Castellino,
1994). The evaluation of the distance deviations (C-
C) in the backbone after superimposition to the starting
FIGURE 5 The Molscript-generated (Kraulis, 1991) diagram of GLA-
EGF1 domains of FVIIa (x-ray crystal structure) and simulated FX. The
backbone atoms of GLA-EGF1 domains (1–82) of the two structures are
superimposed (RMSD  1.52 Å).
FIGURE 6 Representation of calcium-bound GLA and EGF1 domains
of FX based on the snapshot of the 6.2-ns MD trajectory. Calcium ions are
shown in spheres.
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structure, at any given time, provides considerable in-
sight into the structural changes. The plot of distance
deviations of the backbone (C-C) atoms of light chain
is shown in Fig. 7. The deviations are computed based on
backbone alignment of the light chain (solid lines) for
residues Ala1-Arg139 as well as on the alignment of
individual domains (GLA, EGF1, and EGF2 are individ-
ually aligned against the starting coordinates, i.e., at T 
0 ps, shown as a dotted line). The C-C deviations are
large when the entire light chain is used in computing the
distances in contrast to small changes observed when
individual domains are aligned. This difference can be
attributed to the inter-domain movement in the light
chain.
EGF domains are frequently found in extracellular mo-
saic proteins and are characterized by the presence of three
disulfide bridges linked in a characteristic manner (Camp-
bell and Bork, 1993). The EGF1 and EGF2 domains in FX,
as well as in other VKD proteins, act as flexible spacers
between the lipid-binding GLA domain and SP domain.
Their functional role, however, in protein-protein interac-
tions is not fully understood. The influence of the Ca2 ion
at the domain junction on the relative orientations of the
GLA-EGF1 domains has been extensively studied (de-
scribed above). The isolated EGF1 domain binds Ca2 with
intermediate strength, with a Kd of 10
3 M (Persson et al.,
1989). However, the GLA-EGF1 joint domain binds Ca2
ion with a 10-fold increase in Ca2 ion affinity (Persson et
al., 1991; Valcarce et al., 1993). This suggests that the Ca2
ion coordinates with residues from both GLA and EGF1
domains. The available x-ray crystal structures of this re-
gion lack the crucial GLA domain. In its absence, the EGF1
domain can be somewhat disordered in the crystal structure.
Fig. 8 illustrates the GLA-EGF1 inter-domain region with
the Ca2 ion coordination network of FX. The distances of
coordinating oxygen atoms from the calcium ion in the
GLA-EGF1 domain derived from the snapshots of FX and
FXa MD trajectories are also listed in Table 1. The ligands
for the calcium ion at the domain interface are two back-
bone carbonyl atoms of Gly47 and Gly64 as well as the side
chains of Bha-63, Asp46, and Gln49. Two oxygen atoms
from the carboxylate side chain of Bha-63 participate in the
FIGURE 7 C-C deviations in the backbone su-
perimposed structures of light chain: ——, the entire
light chain aligned between the 6-ns snapshot of tra-
jectory and structure at T  0 ps;   , GLA, EGF1,
and EGF2 domains individually aligned.
FIGURE 8 The calcium-ion coordination network at the GLA-EGF1
domain interface of FX.
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coordination (though not shown, the Ca2 ion-binding net-
work is similar in the activated form). Apart from the six
oxygen atoms from the GLA-EGF1 domain, two water
molecules also equilibrated in the coordination sphere, mak-
ing a total of eight ligands to the Ca2 ion in both FX and
FXa simulated structures. This network of calcium coordi-
nation is observed to be stable with the two water molecules
maintaining coordination with the calcium ion throughout
the simulation period.
The RMS fluctuations in EGF2-SP domain (Fig. 3 b) of
FX are small in contrast to the GLA-EGF1 and EGF1-EGF2
inter-domain motions of the light chain (Fig. 3 c). The initial
x-ray crystal structure of FXa from which the current FX
and FXa models were built is characterized by several
H-bonding contacts between EGF2 and the SP domains. A
list of H-bonding interactions between the EGF2 and SP/AP
domains of simulated FXa and FX structures together with
H-bonding information in x-ray crystal structure are shown
in Table 2. These data are collected over the last 1.0 ns of
MD trajectories of both FXa and FX. In the x-ray crystal
structure, Gly204 (backbone oxygen) makes a shared hy-
drogen bond with Thr136 (H and HG1 atoms). In addition,
we also observe the appearance of a weak ion pair between
Arg139 and Asp203. H-bonds with population time over
50% during the last 1 ns of MD trajectory were considered
TABLE 1 Distances of various coordinating oxygen atoms
from calcium ion in the GLA-EGF1 inter-domain binding
region (all distances in Å) of simulated structures of









ASP46 OD2 2.32 2.31
GLY47 O 2.31 2.35
GLN49 O 2.55 2.42
BHA63 OD1 2.28 2.37
OD2 2.39 2.59
GLY64 O 2.47 2.40
Water O 3.05 2.57
Water O 2.73 2.50
TABLE 2 Hydrogen-bonding interactions between EGF2 and SP (or AP) domains of simulated structures of FXa and FX
Donor Residue Acceptor Residue Bond length Bond angle
FXa (simulated) EGF2-SP
NE1 TRP308 HE1 OD1 ASN93 2.85 (2.85) 155.76
NZ LYS134 HZ2 OG1 THR390 2.93 (2.81) 151.35
N THR136 H O GLY204 3.04 (2.80) 150.11
OG1 THR136 HG1 O GLY204 3.00 (3.71) 155.12
N GLY133 H O PRO300 2.91 (2.74) 156.99
NZ LYS388 HZ1 O CYX96 2.86 (3.17) 155.51
N ASN297 H OG1 THR136 3.09 (2.72) 153.80
N TYR391 H O GLY133 2.84 (2.87) 164.02
ND1 HIS101 HD1 OD1 ASP307 2.89 (8.32) 167.06
NZ LYS134 HZ1 OD2 ASP389 2.82 (7.07) 151.81
NH1 ARG113 HH12 OE2 GLU228 2.82 (8.92) 162.96
NH2 ARG113 HH22 OE1 GLU228 2.74 (12.5) 174.32
NE ARG139 HE OD2 ASP203 2.74 (3.20) 163.38
NH2 ARG139 HH21 OD1 ASP203 2.95 (3.20) 149.86
NH2 ARG139 HH21 OD2 ASP203 2.84 (4.10) 143.90
Zymogen (simulated) EGF2-SP
NE1 TRP308 HE1 OD1 ASN93 2.85 141.24
OG1 THR390 HG1 O CYX132 2.66 145.83
NE2 GLN135 HE21 O GLY204 3.13 156.71
OG1 THR312 HG1 OD1 ASN93 3.01 152.97
OH TYR130 HH O VAL298 2.64 153.92
OH TYR130 HH O ARG295 2.67 130.45
ND1 HIS101 HD1 OD2 ASP307 3.32 120.10
EGF2-AP (zymogen, simulated)
NE2 GLN135 HE22 O ASN173 2.75 152.94
N THR136 H OD1 ASN173 2.98 156.84
ND2 ASN173 HD21 O THR136 2.93 161.98
OG1 THR136 HG1 OD1 ASN173 3.08 129.93
NZ LYS134 HZ3 OD2 ASP176 2.77 160.80
NH1 ARG139 HH12 OD2 ASP179 2.77 156.33
NH2 ARG139 HH22 OD2 ASP179 2.85 149.56
NH1 ARG139 HH11 OD1 ASP167 2.87 151.27
The H-bonds that are conserved between the EGF2-SP domains of FXa and FX are shown in bold letters. Ion pairs are shown in italics. All bond distances
are in Å and angles are in degrees. The distances in parentheses represent the corresponding H-bonding distances in the x-ray crystal structure of FXa.
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as stable H-bonds. The data presented in Table 2 reveals
interesting differences between the starting x-ray crystal and
simulated FXa structures. The formation of ion pairs
His101-Asp307, Arg113-Glu228, and Lys134-Asp389 are
not seen in the x-ray crystal structure (1XKA). For instance,
the distance between the ND1 of His101 and OD1 of
Asp307 is 8.3 Å in x-ray crystal structure whereas in the
simulated FXa structure, the same distance is 2.89 Å. Sim-
ilarly, NH2 of Arg113 is 12.5 Å apart from Glu228 as
against 2.74 Å in the simulated solution structure. Also, NZ
of Lys134 is 7.07 Å away from OD2 of Asp389 in x-ray
crystal structure whereas during simulation the same dis-
tance comes close to 2.82 Å. The changes from x-ray crystal
state to solution could be attributed to the crystal contacts
within the cell lattice of FXa. In the present x-ray crystal
structure (1XKA) we found several crystal contacts within
the unit cell (space group P21P21P21). We noticed Asp307
(Asp126) is in contact with Lys60 of the neighboring mol-
ecule. Similarly, the side chain of Asp389 (Asp205) is dis-
placed due to contact with the crystallographic waters.
However, the remainder of the H-bonds between EGF1 and
SP domains identified in the x-ray structure of FXa remains
stable during the simulation.
The zymogen has a number of EGF2/AP hydrogen bonds
that are lost in forming the activated form due to the absence
of the AP in the activated form (Table 2). Residues Thr136,
Lys134, and Arg139 all have different partners in the acti-
vated versus zymogen form. The interactions between
EGF2 and SP domains are also largely different with only
the Asn93-Trp308 and His101-Asp307 interactions rela-
tively the same for zymogen and the activated form. The
total number of interactions of EGF2 and SP domains for
the activated form versus EGF2/(SP  AP) of the zymogen
are nearly identical.
Serine protease domain
The SP domain of FX consists of 254 residues. A critical
difference between the active and zymogen forms of FX
derives from the significant reorientation of the N-terminus
of the SP domain of FXa after cleavage of the AP at the
Arg194-Ile195 (Arg15-Ile16) peptide bond. Upon activation,
the N-terminus end of Ile195 (Ile16) reorients into the inte-
rior of the SP domain and becomes stabilized by the for-
mation of a strong salt bridge (ion pair) with Asp378
(Asp194). This event is crucial to trigger the events that
facilitate the catalytic activity of FXa.
The RMS fluctuations of the SP domain of FX are sta-
bilized over the simulation time with no significant changes
seen in the last 2 ns (Fig. 3 b). Recall that the initial
structure of the zymogen was derived from the inhibitor-
bound FXa. In this process, the N-terminal region of FXa
was restructured to provide the initial zymogenic form
based on the available crystal structures of zymogens of SP
coagulation proteins. We used the chymotrypsinogen/chy-
motrypsin pair as the model for constructing the AP region.
To compare the overall changes in the SP domains of
activated and zymogenic FX, we computed the C-C
distances between the x-ray crystal structure of FXa and the
simulated solution structure of FXa (after optimal superpo-
sition) for residues Ile195-Lys429. The plotted distances are
shown in Fig. 9 a. A similar plot between the simulated
structures of FXa and the zymogen is shown in Fig. 9 b. It
is evident from Fig. 9 a, that several regions have moved
(x-ray versus simulated FXa). Noticeably, three loop re-
gions corresponding to residues Thr312, His328, and
Lys370 show significant C-C deviations. These residues
are found in regions that are on the surface-exposed loops of
the SP domain. Interestingly, the catalytic triad residues
FIGURE 9 C-C deviations in the backbone superimposed structures of the serine protease domains of FXa (x-ray) versus FXa (simulated) (a) and
FXa (simulated) versus FX (simulated) (b).
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(His236, Asp282, and Ser379) show small deviations
(marked by vertical lines) for both plots. In fact, when the
backbone atoms of the three catalytic residues are superim-
posed, the RMS differences of FXa and FX with starting
x-ray crystal structure are 0.30 Å and 0.54 Å, respectively.
The RMSDs of the backbone and the side-chain atoms of
the x-ray crystal structure compared with the simulated FXa
for residues Ile195-Lys425 are 1.05 Å and 2.03 Å, respec-
tively. Analysis of several inhibitor-bound FXa crystal
structures revealed that the side-chain conformation of
Ser379 (Ser195) varies considerably depending on the struc-
ture of the inhibitor and the nature of its interactions with
the active-site triad. For example, the inter-atomic distance
between the ring nitrogen atom (NE2) in His236 (His56) and
the side-chain hydroxyl group oxygen atom (OG) in Ser379
(Ser195) varies from 2.93 Å to 4.05 Å in eight crystal forms
of active-site-inhibited FXa structures (PDB entries 1XKA,
1XKB, 1HCG, 1FAX, 1FJS, 1F0R, 1F0S, and 1EZQ). This
variation is due to the structural changes in the active-site
pocket caused by the binding of various inhibitors. We
started our initial simulations of FXa from a model based on
the x-ray crystal structure (PDB 1XKA) (Kamata et al.,
1998) for which the NO distance between His236 (NE2)
and Ser379 (OG) was 3.86 Å. This distance remains con-
stant during the simulation period, and no H-bonding is
observed between His236 and Ser379. In contrast, the zy-
mogenic form has a stable H-bond between the NE2 of
His236 and OG of Ser379 (2.75 Å) that is stable throughout
the simulation period. However, the side-chain conforma-
tion of Ser379 (Ser195) in both the starting crystal structure
and the simulated FXa appears to be in an orientation
different from the simulated zymogenic FX. For FX, we
find a change in the backbone conformation of the neigh-
boring residues (loop region involving residues Ala365-
Asp378) of Ser379 (Fig. 9 b). Some change is expected
because Asp378 in this loop region is involved in an ion-
pair interaction with the N-terminus of Ile195 (this interac-
tion is not present in the zymogenic form of FX). The initial
model of zymogen FX is based on chymotrypsinogen in
which the conformation of the side chain of Asp194 (corre-
sponds to Asp378 in FX) has a different orientation when
compared with the corresponding activated chymotrypsin
structure. Because the modeling of FX is based on the
activated FXa x-ray crystal structure, the initial orientation
of the side-chain conformation of Asp378 was similar to the
activated FXa. However, during the first 3 ns of MD sim-
ulation of FX, we observed that the conformation defined by
–C-C- of Asp378 remained near the initial state despite the
absence of the ion pair between Asp378 and Ile195. Al-
though a much longer trajectory might bring about the
necessary conformational changes in the Asp378 residue,
we applied torsional restraint on the backbone atoms of
Asp378 to force the conformation of Asp residue to be
similar to that of the Asp194 of chymotrypsinogen. The
restraint was applied for 400 ps (from 3.0 to 3.4 ns). The
simulation was then continued to 6.2 ns without torsional
restraints.
The regions with major C-C distances between the
FX (simulated) and FXa (simulated) occur in the external
loops associated with the SP domain (Fig. 9 b). They are
calcium ion (Asp250-Glu260) and the putative sodium ion
(Gly400-Gly410) binding sites as well as the loop region
(Ala365-Asp378) near the active site and Thr327-Arg332
loop between the two cation-binding regions. The changes
in the C-C distances near the active-site (loop region
365–378) and in the putative Na-ion-binding loop (400–
410) are particularly noteworthy. The major difference in
C-C between FX and FXa near Asp378 (Asp194) origi-
nate from the conformational changes that occurs upon
formation of the ion pair between Asp378 and Ile195 in FXa
(absent in the zymogenic form).
To focus on the critical differences between the activated
and zymogenic forms of the SP domain, we examined the
electrostatic potential (ESP) near the active-site region. The
ESP maps of zymogen and activated SP domains are shown
in Fig. 10, a and b, respectively. Both structures of the SP
domain are in the same orientation after aligning the back-
bone atoms of the active-site residues Asp282, His286, and
Ser379. Various residues in the binding pockets of the
active site together with the catalytic triad are marked in the
Fig. 10 a. The cleavage site Arg194-Ile195 in zymogen is
also shown by a circle (labeled 12) in the figure. A positive
potential (the blue region in the circle) exists at the site that
involves peptidyl cleavage by incoming proteolytic en-
zymes. Although the GRASP-derived (Nicholls et al., 1991)
ESP maps can give only a qualitative picture of the differ-
ences between the two structural forms, changes around the
active site are apparent. The active-site pocket in zymogen
is wider and more solvent exposed than the activated form.
The electrostatics of the side chain of residue Gln376
(marked 8 in the figure) that helps define the specificity
pocket (S1 site) in activated FX is clearly different from the
zymogen structure. Whereas the orientation of this side
chain restricts the accessibility of active-site residue Ser379
(marked as 1 in Fig. 10), the same residue in the zymogen
structure is displaced. The CA-CA distance (calculated after
superimposing the backbone atoms of catalytic triad resi-
dues of FX and FXa) between Ser379 and Gln376 (S1 site)
is 5.28 Å in the simulated FXa (corresponding distance in
x-ray crystal structure is 6.61 Å), whereas it is 8.21 Å in the
simulated zymogen. This deviation of 3.0 Å may be
significant because the S1-specificity pocket largely deter-
mines the functional activity of activated FX (Rezaie and
Esmon, 1995). Recall also that the ion pair between the
N-terminus end of Ile195 and Arg378 is located near the
S1-specificity pocket. Other specificity pockets around the
active site appear to have little change of the backbone
C-C distance. For instance, the C-C distance be-
tween Ser379 and Tyr279 (S4 specificity site) is 7.1 Å in
both FXa and FX. The same is true for the distance between
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Phe356 and Tyr279 (14 Å). The difference in the S1-
specificity pocket in FX and FXa is also shown by the
differences in the solvent-accessible surface area (SASA)
near the active-site region. The SASA around the catalytic
residue Ser379 (Ser195) within a 7-Å sphere is evaluated
using a probe radius of 1.4 Å. The SASA values were
calculated by the ACCESS program in the WHATIF pack-
age for nonhydrogen atoms (Vriend, 1990). This area covers
all the catalytic triad residues and several specificity pockets
around the active site. A total of 30 residues were found in
FXa and 25 residues in FX around Ser379 within the 7-Å
radius. The SASA values for this region are 393 Å2 and 471
Å2, respectively, for FXa and FX.
The distance between the active-site residues in the SP
domain and an imaginary phospholipid surface has been
investigated. Although earlier fluorescence studies sug-
gested an approximate distance between the surface and the
active site to be 61 Å (Husten et al., 1987), later studies
using the same techniques but different fluorescent probes
suggested it to be 83  3 Å for FXa (Yegneswaran et al.,
1997). Similar measurements for the zymogen have not
been made (to our knowledge). We are able to show the
time dependence of the distance between the calcium ion
plane (our model surface) and the Ser379 (Ser195) residue in
the active-site cleft that plays a crucial role in catalytic
function. Fig. 11, a and b, shows the changes in the distance
over simulation time for FXa (Fig. 11 a) and FX (Fig. 11 b).
FIGURE 10 Electrostatic potential maps of
serine protease domains of zymogen (top left)
and activated (bottom left) structures of FX gen-
erated by the GRASP program (Nicholls et al.,
1991). Both structures represent similar orien-
tation with the backbone alignment of the three
catalytic triad (His236, Asp282, and Ser379)
residues. Various residues around the active-site
pocket are marked. The residues corresponding
to the numbering are as follows: 1, Ser379; 2,
His236; 3, Asp282; 4, Lys276; 5, Tyr279; 6,
Trp399; 7, Ser398; 8, Gln376; 9, Gln240; 10,
Na-binding region; 11, Ca2-binding region.
The same numbering is used for both activated
and zymogen structures. In addition, the cleav-
age site of zymogen at Arg194-I195 (12) is
circled in the structure. The ESP of full zymo-
gen structure derived from the last snapshot (6
ns) is also shown in the figure (right). Different
domains of FX are marked in the figure. Re-
gions of EGF2 and AP domains that might be
involved in negative electrostatic repulsion are
marked in circles.
FIGURE 11 Changes in the distance between the plane of GLA calcium
ions (three calcium ions in the core of the GLA domain) and Ser379
(backbone atom CA) of Fxa (a) and FX (b).
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The distance in the FXa is largely stabilized over the last
500 ps of simulation time and remains stable at 83  2 Å.
This is encouragingly similar to the reported experimental
value (Yegneswaran et al., 1997). This distance is calculated
to be 95  3 Å for the zymogenic form. The zymogenic
form of FX thus appears more extended than the active
form, indicating conformational and orientation difference
between the active and zymogenic FX. The rationale for this
difference might be seen in the ESP map of FX. The ESP of
full zymogen structure derived from the last snapshot of
MD trajectory (6.2 ns) is shown (Fig. 10 c) together with the
ESP maps of EGF2-SP domains of FX and FXa (Fig. 10, a
and b). There is electrostatic repulsion between part of the
EGF2 residues and AP for FX (shown in circles), which
might result in displacing the AP domain from the EGF2
domain in FX. Also, the restructuring of the EGF2 and SP
interactions (FX versus FXa) could result in a more ex-
tended conformation. Upon removal of the activation pep-
tide in the coagulation pathway, the repulsion originating
from the AP residues is deleted. Thus, the surface of the SP
domain, which is buried under AP in FX, is exposed in FXa.
The newly exposed region of FXa is predominantly hydro-
phobic or neutral (not shown). Consequently, FXa could
respond by contracting somewhat. In Fig. 12, we show a
snapshot of FXa and FX that are aligned to the backbone
atoms of GLA and EGF1 domain (Ala1-Glu82; RMSD 
2.4 Å). It is evident from the figure that the zymogenic and
activated forms of FX adopt distinctly different conforma-
tions in the SP domain.
Calcium-binding site in SP
The consensus calcium-binding loop in the SP domain has
an important functional role in protecting the SP domain
from proteolysis (Sabharwal et al., 1997) and enhancing the
amidolytic activity of factor Xa (Sherill et al., 1988). Also,
the calcium-binding site may participate in the prothrombi-
nase complex formation (Chattopadhyay et al., 1992). This
site is well characterized in trypsin and other serine protein-
ases (Bode and Schwager, 1975). It has been reported
recently that Ca2 ion potentiates the S-2222 hydrolytic
activity of factor Xa by 1.6-fold (Sabharwal et al.,
1997). Although the site is conserved in most of the serine
protease domains, the binding affinity varies depending
upon the coordination pattern. In the initial x-ray crystal
structure from which the FX model was built, the calcium
ion is coordinated with six atoms in the loop region
(Asp250-Glu260) of the SP domain. These are the side-
chain carboxylate oxygen atoms of Asp250 (OD1), Glu257
(OE2), Glu260 (OE1 and OE2), and the main-chain oxygen
atoms of Asn252 and Gln255. The distances of the coordi-
nating atoms from calcium ion are tabulated in Table 3 for
the x-ray crystal structure of FXa and the simulated struc-
tures of activated and zymogenic FX. Several of the coor-
dinating oxygen atoms are loosely defined in the x-ray
crystal structure, particularly the carboxylate side chains of
Glu257 (OE2:3.38 Å) and Glu260 (OE2:4.76 Å). In addi-
tion, no crystallographic waters are found within coordina-
tion shell (within 4 Å) of the calcium in the x-ray crystal
structure. However, as the solution MD simulations
progress, all of the coordination oxygen atoms around the
calcium ion contract to a tightly bound anti-prism coor-
dination complex that includes two oxygen atoms from
the first-shell water molecules (Fig. 13). A similar type of
coordination network of Ca2 ion bound to the SP do-
main was observed in the MD study of protein C (Perera
et al., 2000). The backbone alignment between FXa (x-
ray) and simulated FXa structure shows major changes in
the loop region as discussed above, and one of the major
deviations in the C-C distance (Fig. 9 a) stems from
FIGURE 12 The conformational difference between the active and zy-
mogenic forms of FX when the backbone atoms of the GLA and EGF1
domains of the two structures were aligned. Superimposition of GLA-
EGF1 domains used the residues 1–82 of both structures. The zymogen
structure is shown in thick coils while the activated form is in thin coil.
Activation peptide of FX is represented in solid coil form. The SP-bound
calcium ions are also shown as spheres.
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the calcium-ion-binding region. However, the coordina-
tion pattern of calcium-binding region is similar in the
simulated structures of both activated and zymogenic
forms as shown in Table 3.
Structural impact of genetic mutations on
zymogen structure
What can be said about the relationship between lesions
known to have physiological consequences and the simula-
tion structures that we have constructed? We examined the
mutation databases (Cooper et al., 1997; Millar et al., 2000)
for mutations with known bleeding disorders. Several of the
mutations are at locations where an effect is almost certainly
expected: for Cys109Tyr (loss of disulfide bridge in EGF2),
Arg139Cys (loss of cleavage site recognition), Ile231
(frame shift and loss of translation), Asp282Asn (the active
site aspartic acid is critical for catalytic function; asparagine
would not support the essential proton shuttle). The reasons
for the effect of other mutations is more problematic.
Gla14Lys
For Gla14Lys, the Ca(II)-ion induced folding is essential for
proper phospholipid interaction of the protein. That the
effect of this mutation is mild is surprising because it is a
3 charge change (Watzke et al., 1990). However, whereas
several of the Gla groups are involved in multiple calcium
ion interactions, Gla14 interacts with only one calcium ion
in a malonate-like coordination; the calcium ion also has a
malonate interaction with Gla19 that may prevent total
unfolding. (The ionic interactions of Gla14 are the same in
both simulation and the x-ray crystal structure.) Because the
mutant Gla25Lys also leads to only mild clinical effect
(Nobauer-Huhmann et al., 1998), it may be that the unit
[-K-] functions somewhat as [-GlaCa(II)] spatially and
electrostatically; otherwise, subsequent unfolding would re-
FIGURE 13 The coordination network of
the calcium ion bound to the SP domain of FX.
The anti-prism coordination of eight oxygen
atoms includes two water molecules from the
solvent. The coordination pattern is similar in
FXa.
TABLE 3 Distances of coordinating oxygen atoms in the
calcium-binding region of the serine protease domain (all
distances in Å) observed in the starting x-ray structure of
FXa and simulated structures of FXa and FX (based on











ASP250 OD1 2.83 2.28 2.29
ASN252 O 2.67 2.43 2.42
GLN255 O 2.52 2.40 2.48
GLU257 OE2 3.38 2.31 2.33
GLU260 OE1 2.81 2.33 2.37
OE2 4.76 2.42 2.40
Water O –* 2.88 2.63
Water O – 3.00 2.43
*Not found in the x-ray crystal structure.
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move function. Why the mutations Gla14Lys and Gla25Lys
are not more devastating is intriguing and worthy of addi-
tional structural study.
Asn57Thr
Asn57 is conserved in human and bovine FVII, FIX, and
FX. In all three of the structures of our study (both simu-
lation and x-ray), the side chain of Asn57 interacts via
H-bonding with the backbone oxygen atom of Cys81, a
residue near the C-terminus of the EGF1 domain. This
interaction would be lost with the mutation to Thr. Asn57 is
located near the critical Ca(II) ion site in EGF1, although it
does not appear to interact directly with the Ca(II) ion.
Gly114Arg
This conserved residue is in a 14-member disulfide loop in
the EGF2 domain. It is reasonable that the side chain of the
mutant can either reach the SP domain for a disruptive salt
bridge interaction or can block interaction with VIIIa/IXa,
VIIa/TF, or Va/II.
Val298Met
Amino acids at this position are hydrophobic in the VKD
proteins: valine for VII, IX, and X and isoleucine for II and
protein C. In all three FX structures (simulation and x-ray),
this residue is deeply buried. There appears to be no room
for the extra size of Met (as compared with Val for factor
X), and so the clinical manifestation (severe) suggests that
unfolding occurs.
Thr318Met
This is a surface location. Thr318 is involved in a side-chain
hydrogen bond with Glu341 in all of our structures (simu-
lation and x-ray) that would be lost on mutation. Either this
loss or some undefined specific protein-protein interaction
leads to the clinical effect.
Gly323Ser
The glycine at position 323 is buried. The sequence
Val(Thr/Ser)Gly323 (Trp/Phe)Gly is substantially con-
served across II, X, IX, VII, and protein C. It is at the end
of the -sheet structure. Replacement by serine should
disrupt this structure.
Arg326Cys
The arginine at position 326 is a surface residue. It is located
at a site analogous to the thrombin anion-binding exosite
(fibrinogen-binding site) and thus may be involved in pro-
tein-protein interactions that require the positive charge of
the arginine. The side chain in all three structures (simula-
tion and x-ray) interacts with Gln376, which is located at the
S1-binding site.
Pro343Ser
The proline is a conserved residue involved in a surface
-sheet. The sequence GDSGGP(343) is conserved across
the VKD proteins II, X, IX, VII, and protein C. The impli-
cation is that the mutation affects intrinsic folding, perhaps
by adding the full backbone H-bonding not present with
proline or adding side-chain H-bonding. A more complete
comparison of the structural features of three structures
(simulations for X and Xa and x-ray crystal structure of Xa)
will follow at a later time.
CONCLUDING REMARKS
We have developed a complete structural model for both
activated and zymogenic forms of FX using state-of-the-art
modeling procedures. We have shown through solution MD
simulations that both structures share similar intra-domain
motifs in the light chain. Upon activation, however, FX
reorients so that the zymogenic structure is, on the average,
10 Å longer than the activated structure along the long
axis. The active-site region in the zymogenic state shows
marked differences near the catalytic triad when compared
with the activated structure, but the backbone atoms of the
catalytic triad residues are similar in both forms. The S1-
specificity pocket differs significantly in the two structural
forms, and the active-site pocket is wider and more solvent
exposed in zymogen than the activated form.
The multi-site interactions that occur between FX and
TF-VIIa complex are not fully established. Recent studies of
possible interactions among the several domains of the two
proteins revealed that the GLA domains of FX and VIIa
interact. For instance, mutational studies suggest that Arg36
of VIIa plays a key role in substrate interactions (Ruf et al.,
1999). Similarly, the GLA domain of FX has been impli-
cated in the interaction with the TF-VIIa complex based on
the study of several mutants in the GLA domain of FX (Kim
et al., 1995; Rudolph et al., 1996). TF residues Lys165 and
Lys166 have been shown to contribute to protein-protein
interactions with FX in the ternary TF-VIIa-FX complex
(Ruf et al., 1992). The fragment His263-Lys276 in FXa has
been implicated in specific binding of factor V/Va in the
prothrombinase complex (Chattopadhyay et al., 1992). In
the present model of zymogenic FX, the peptidyl cleavage
site at Arg194-Ile195 bond is 84 Å from the Ca2-binding
surface of the GLA domain. The distance of Ser344 (Ser195)
in the catalytic triad of VIIa to the plane of Ca2-binding
surface is 85 Å in the x-ray crystal structure (Banner et al.,
1996). Thus, both substrate (FX) and enzyme complex
(TF-VIIa) possess an optimal length from the corresponding
GLA surfaces to the cleavage-site and active-site residues.
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The simulations described in this paper must be charac-
terized by any means as brute force. It thus is reasonable to
ask if the methodology employed is the best that we can do
for large systems (105 atoms) and long times (5 ns). It
is probably so at the present time. Other promising methods
are currently being tested, however. The generalized solvent
boundary potential method (Im et al., 2001), the all-atom
Brownian dynamics method (Shen et al., 2001), and the
Langevin/multiple-time-step algorithm (Batcho et al., 2001)
provide a compromise between speed and accuracy. Algo-
rithms for obtaining free energies from MD are also being
tested (Kollman et al., 2000; Lee and Kollman, 2001). The
addition of snapshot free energies along the trajectory could
greatly increase the useful information derivable from long
simulations such as presented here. We ultimately will
implement this technique in our applications. Most promis-
ing is the development of algorithms that provide for opti-
mizing PME parameters in the context of multiple-time-step
capability (Batcho et al., 2001). The latter may be capable of
speedups of over a factor of two without loss of accuracy.
We look forward to the general availability of these codes.
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